Navigation Links
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
Date:5/30/2009

myeloma patients."

About Carfilzomib

Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, and renal cell carcinoma.

Proteolix is conducting a comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including an ongoing accelerated approval study in heavily pre-treated relapsed/refractory patients and a Phase 2 clinical trial in relapsed patients stratified by prior treatment with bortezomib. Both Phase 2 clinical trials are being conducted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC). A Phase Ib clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the latest information regarding ongoing carfilzomib clinical trials, please visit www.clinicaltrials.gov.

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Proteolix is also developing a pipeline of novel
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
2. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
7. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
10. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
11. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...wire/ -- StemCyte, Inc. concluded an exclusive lic... Sinica, the National Laboratory of Taiwan, for ce...y (IP) related to the treatment of Chronic Stroke ... by a team led by Professor John Lin, MD, PhD and ...ently the exclusive collaborator with StemCyte on ...
(Date:11/30/2009)... eHealthSource.com launched the fir...roducts approved for Flexible Spending Account or ... is also the first to exclusively carry value-bran...p to 75 percent on everyday healthcare needs. ,... headaches - high costs and complexity," says eHea...
(Date:11/30/2009)... Health Robotics today announced,it...nd product specifications,for a new and revolution...on", a new key component of its i.v. Room of the F...ooth # 114). , "I look forward to see the...lueprints and to find out if TPNstation appears to...
Breaking Medicine Technology:StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 2StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 3eHealthSource.com Launches Online Shopping Site Dedicated to Over-the Counter Medications Approved for FSA/HSA Claims 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 3Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 1Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 2Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 1Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 2Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 3Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 4Bones May Suffer From Green Tea Consumption 57484 1
...raging Response in CF Patients - Results Validate..., BETHESDA, Md., March 27 The Cystic Fibrosis Fo... in development that targets a,basic defect in CF,...linical trial for patients who carry the G551D mut... Pharmaceuticals Incorporated., Patients who took...
...epligen Corporation,(Nasdaq: RGEN ) announced tod...al trial to evaluate the use of RG1068, synthetic ...eatic duct structures by magnetic resonance,imagin...eline-controlled,single dose study in which approx...I followed by a secretin-enhanced MRI of the pancr...
Other Medicine Technology:Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 2Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 2Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 4
(Date:11/30/2009).../ -- Physicians at Beth Israel Deaconess Medical C...y demonstrating the potential for automated analys...OR Analyzer System® to assist in rapidly ruli...ncy department (ED ) patients with chest pain. The...e of cCTA has potential to significantly reduce un...
(Date:11/30/2009)... response to a "cocaine-cues" video, active cocain...ity in brain regions linked to drug craving, accor...gy,s Brookhaven National Laboratory. The results, ...e , suggest that clinical interventions designed t... cocaine abusers stop using drugs and avoid relaps...
(Date:11/30/2009)...ore often than younger people, study finds, , ... people who are problem drinkers consume more alco...finds, possibly because they need more alcohol to ...y released this month, people dependent on alcohol... a week, on average. By contrast, younger alcoholi...
(Date:11/30/2009)...30 Baxa Corporation is sponsoring ...re of safety" means in today,s pharmacy environmen...a Culture of Safety in Pharmacy ," features a pane...experiences with culture of safety, what it takes ...ole of technology in enabling or inhibiting safe p...
(Date:11/30/2009)...swire/ -- A new study has found that 27% of Medica...ustomers have a current intention to shop for and ...re is up from 20% in 2008. Over the past four yea...eading indicator of actual switching patterns. W...tually will leave their current insurer for anothe...
Breaking Medicine News(10 mins):Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 3Health News:Brain scan study shows cocaine abusers can control cravings 2Health News:Brain scan study shows cocaine abusers can control cravings 3Health News:Binge Drinking Not Just a Rite of the Young 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 3Health News:More Seniors Considering Health Insurance Switch 2
...ufacturing industries may be able to repair heart ...fering from muscular dystrophy. Duchenne musc...ms of muscular dystrophies that are characterized ... Mostly incurable, this disease causes congenital ...
...r the International Society for Biomedical Researc...enting their research paper on alcohol abuse and c... and treatment is more beneficial than any other f...addiction while it is at a still early stage. The ...
...at the ''morning after'' contraceptive pills work/... fertilization and not by preventing implantation ...s demonstrated the phenomenon in a controlled clin...inhibit or postpone ovulation; pregnancy rates amo...
...nted out that taking beer is very good// for healt...e health benefits as a glass of red wine. Ac... drink of beer or stout contributes an amount of a...ul. The study says that larger daily intakes ...
...incurable disease can opt for mercy killing// in N...isease and with severe suffering may have the choi...Society has plans of adopting national guidelines ...ircumstances and under strict conditions... delibe...
...giene maintained by the health workers may cause a...says a new study. Researchers from University...of lawsuits, it is the negligence of the health wo...e number of deaths that would have been avoided if...
Other Medicine News:
Hunkeler IOL Manipulator
Guimaraes ICL Manipulator
Lester IOL Manipulator
...scopes are individually adjusted for perfect focus...s, along with Keeler's wide angle light beam and i... pupil size, you will see the clearest and largest...longer life battery and fast charge capability. Wi...
Medicine Products: